FDA Accepts Supplemental Biologics License Application For KEYTRUDA
Lung Cancer, News
Merck recently announced that the U.S. Food and Drug Administration (FDA) has agreed to review a supplemental Biologics License Application (sBLA) for the company’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab), with the ... Read more